Cartesian Therapeutics, Inc. — Director's Dealing 2021

Mar 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2021-03-17

Reporting Person: TRABER PETER G (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-17	Common Stock	P	10000	$4.5295	Acquired	88000	Direct
2021-03-18	Common Stock	P	10000	$4.50	Acquired	98000	Direct

Footnotes

F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.525 to $4.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.